EUVIMEDEUVIMED entdecken
Open Access

PpSP42 and LmSTI1-PpSP42 Recombinant Proteins from Phlebotomus papatasi and Leishmania major Confer Protection Against Leishmania major Infection in BALB/c Mice

Fariborz Bahrami iD, Touraj Miandoabi iD, Vahideh Moein Vaziri iD, Farhad Riazi-Rad iD, Soheila Ajdary iD

Advanced Pharmaceutical Bulletin · 15.06.2026 · 16 (2) · 432-444

DOI: 10.34172/apb.45925 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Pharmaceutical Bulletin, online erschienen am 09.05.2026. Verfasst von Fariborz Bahrami und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Pasteur Institute of Iran, Tehran, Iran. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Cutaneous leishmaniasis (CL), a parasitic skin disease transmitted by sand flies, is characterized by complex interactions between Leishmania parasites and sand fly saliva, influencing both transmission and disease progression. This study investigated the immunogenicity of partial Phlebotomus papatasi salivary protein PpSP42 (or PP42 in short) and a novel recombinant fusion protein composed of Leishmania major stress-inducible protein 1 (LmSTI1) and PP42, produced in Escherichia coli.

Methods

BALB/c mice were immunized subcutaneously with the fusion protein or with PP42 subunits separately, using resiquimod as an adjuvant, and subsequently challenged with L. major promastigotes and sand fly salivary gland homogenate. Lesion development and parasite burden as well as immune responses were evaluated by measuring key cytokines (IFN-γ, IL-4, IL-10, TNF-α) and antibodies (IgG, IgG1, IgG2a) up to eight weeks post-challenge.

Results

Immunization with either PP42 or the fusion protein significantly attenuated lesion development (30-40% reduction in lesion size after 8 weeks; P

Schlagwörter

Stichwörter der Autor:innen

BALB/c miceCutaneous leishmaniasisImmunogenicityLeishmania majorLmSTI1Sand fly saliva

Autor:innen und Institutionen

  • Department of Immunology, Pasteur Institute of Iran, Tehran, Iran.
  • Department of Parasitology and Mycology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Fariborz Bahrami, Touraj Miandoabi, Vahideh Moein Vaziri, Farhad Riazi-Rad, Soheila Ajdary

Zitieren

APA

Bahrami, F., Miandoabi, T., Moein Vaziri, V., Riazi-Rad, F., & Ajdary, S. (2026). PpSP42 and LmSTI1-PpSP42 Recombinant Proteins from Phlebotomus papatasi and Leishmania major Confer Protection Against Leishmania major Infection in BALB/c Mice. Advanced Pharmaceutical Bulletin, 16(2), 432-444. https://doi.org/10.34172/apb.45925

Vancouver

Bahrami F, Miandoabi T, Moein Vaziri V, Riazi-Rad F, Ajdary S. PpSP42 and LmSTI1-PpSP42 Recombinant Proteins from Phlebotomus papatasi and Leishmania major Confer Protection Against Leishmania major Infection in BALB/c Mice. Advanced Pharmaceutical Bulletin. 2026;16(2):432-444. doi:10.34172/apb.45925

BibTeX
@article{Bahrami2026,
  author = {Bahrami, Fariborz and Miandoabi, Touraj and Moein Vaziri, Vahideh and Riazi-Rad, Farhad and Ajdary, Soheila},
  title = {PpSP42 and LmSTI1-PpSP42 Recombinant Proteins from Phlebotomus papatasi and Leishmania major Confer Protection Against Leishmania major Infection in BALB/c Mice},
  journal = {Advanced Pharmaceutical Bulletin},
  year = {2026},
  volume = {16},
  number = {2},
  pages = {432--444},
  doi = {10.34172/apb.45925}
}
Kostenlos starten →